Latest Breaking News On - சுகாதாரம் ராயல்டி மேலாண்மை - Page 4 : comparemela.com

HealthCare Royalty Management: HCR Expands Team and Announces Promotions

HealthCare Royalty Management: HCR Expands Team and Announces Promotions Expansion of West Coast Presence: HCR has appointed Matthew H. Bullard as a Managing Director based in San Francisco, CA. We are very pleased to welcome Matt to the HCR team, said Clarke B. Futch, Chief Executive Officer and Chairman at HCR. With over two decades of healthcare experience, Matt brings a wealth of knowledge and relationships to HCR. Matt will round out HCR s team on the West Coast, which has been one of our most important markets. Matt s addition along with HCR s existing professionals on the West Coast, Sean Mansoory, Mardi Dier (Senior Advisor) and Gary Lyons (Senior Advisor), demonstrates HCR s commitment to its regional model and provides the firm with more scale and depth to better serve the needs of biopharmaceutical companies in that region.

United statesCity ofUnited kingdomSan franciscoSean mansooryCarlos almodClarkeb futchChris whiteShinw kangLos angelesKostenloser wertpapierhandelMatthewh bullardAnthony rapsomanikisAmogh sivarapatnaCoast business developmentYale university

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Aclaris Therapeutics (NASDAQ:ACRS) - The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Aclaris Therapeutics (NASDAQ:ACRS) - The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Neurocrine biosciencesHarvard biosciencesJohn schroerRobert prentissHarvard bioscience incRegenxbio incSupernus pharmaceuticals incVirios therapeuticsCellectar biosciences incGilead sciences incHalozyme therapeutics incMerck co incPfizer incSpectrum pharmaceuticals incSoligenix incNeurocrine biosciences inc

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma® Royalties for $200 Million - Agreement with Healthcare Royalty enables REGENXBIO to advance its broad gene therapy pipeline, including pivotal program for RGX-314 News provided by Share this article Share this article ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it has entered into an agreement to sell a portion of the royalty rights due to REGENXBIO from Novartis Gene Therapies from the net sales of Zolgensma® to entities managed by Healthcare Royalty Management, LLC (HCR) for a gross purchase price of $200 million. This transaction provides immediate, non-dilutive capital to REGENXBIO for continued innovation in the development of potential breakthrough gene therapies for patients and comp

United statesCity ofUnited kingdomSan franciscoDavid rosenClarkeb futchTricia truehartEleanor barisserTechnology platformMorgan lewis bockiusTechnology platform licenseesExchange commissionCovington burlingHealthcare royalty managementCorporate communicationsSecurities exchange